Lv4
428 积分 2025-09-28 加入
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers
1天前
待确认
Design principles of lipid nanoparticles for RNA delivery
3天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
4天前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
4天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
5天前
已完结
515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
5天前
已完结
Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity‐induced insulin resistance
9天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
10天前
已完结
Process Development and Scale-Up of a Novel Route to 8Aminooctanoic Acid
15天前
已完结
Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate
2个月前
已完结
皖公网安备34019202002308
